Inhouse Drugstore Europe Xenical for weight loss
 
Xenical For Weight Loss & Obesity
About Privacy Policy
Search for..  View the contents of your Shopping Cart
Frequently Asked Questions Contact Details Inhouse Drugstore (USA)  Inhouse Drugstore (UK)  Japanese Language Site
Xenical, Cellasene and other Weight Loss Medications Fincar,Finpecia,Generics Vetmedin, Vivitonin Ventolin, Singulair and other Asthma & Allergy Treatments Relenza and other General Medications Lipitor, Zocor and other Medications for a Healthy Heart Skin Treatments Smoking Cessation Medications
Anti Depressants Propecia ,Proscar and Hair Loss Treatments Celebrex,Vioxx and Arthritis Pain Relief Timoptol, Timoptic Birth Control Products and Hormones Mens Specialties Specialised Products for Women and Hormone Replacement Therapy
Infections Diabetes Ultram and other Pain Medications Aids / HIV Digestive Neurological Transgender
Inhouse Drugstore Europe
 

 
   Xenical Articles


Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

 

 Xenical: Prices and Ordering Information

Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ

University of Colorado Health Sciences Center, Denver, USA.

1 : Am J Clin Nutr 1999 Jun;69(6):1108-16

BACKGROUND:

Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment.

OBJECTIVE:

This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain.

DESIGN:

Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28-43], 729 subjects lost > or =8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase.

RESULTS:

After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 4.5% compared with 58.7 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained < or = 25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001).

CONCLUSION:

The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.

Publication Types:

Clinical trial

Multicenter study

Randomized controlled trial

Comments:

Comment in: Am J Clin Nutr 1999 Jun;69(6):1059-60

Comment in: Am J Clin Nutr 1999 Jun;69(6):1061-3




Inhouse Drugstore Europe    Inhouse Drugstore Europe

 

  Xenical, Cellasene and other Weight Loss Medications

Weight Loss
Medications


XenicalXenical

Non Prescription
Supplements

Chitosan
Fat Metaboliser
Super Fat Burners
Citrimax
Evening Primrose Oil

Articles & Studies
 
Xenical
Chitosan
L-Carnitine
HCA
Weight Loss
Supplements